<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="924">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05361382</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY22020056</org_study_id>
    <secondary_id>R01AG073267</secondary_id>
    <nct_id>NCT05361382</nct_id>
  </id_info>
  <brief_title>Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease</brief_title>
  <acronym>HEAD</acronym>
  <official_title>Longitudinal Multicenter Head-to-Head Harmonization of Tau PET Tracers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tharick Pascoal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare/harmonize cross-sectional and longitudinal tau tangle&#xD;
      measurements obtained with the tau PET radiopharmaceuticals Flortaucipir and MK-6240 to&#xD;
      elucidate the advantages and caveats of their use in clinical trials/practice and provide&#xD;
      parameters to integrate their estimates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a longitudinal, multi-site, non-randomized study in which the participants will&#xD;
      undergo Flortaucipir and MK-6240 PET scans at baseline and approximately at 18-month&#xD;
      follow-up. At each time point, participants will also have an amyloid-β PET scan, magnetic&#xD;
      resonance imaging, detailed cognitive tests, and a blood draw for biomarker quantification.&#xD;
      The main objectives of this study are standardizing tau PET tracers' outcomes and comparing&#xD;
      their performance.&#xD;
&#xD;
      To accomplish our objectives, the investigators propose the following specific aims:&#xD;
&#xD;
      In Aim 1, investigators will standardize tau PET processing methods, convert the tracers to a&#xD;
      common scale, compare associations with amyloid-β, atrophy, and cognition, and&#xD;
      compare/harmonize Braak staging assessments between tau tracers using cross-sectional data.&#xD;
&#xD;
      In Aim 2, investigators will ascertain the optimal processing method for longitudinal&#xD;
      analysis and compare longitudinal changes in tau accumulation obtained with the tau PET&#xD;
      radiopharmaceuticals and their associations with changes in amyloid-β, atrophy, and&#xD;
      cognition.&#xD;
&#xD;
      In Exploratory Aim 3, investigators will compare cross-sectional and longitudinal&#xD;
      Flortaucipir and MK-6240 estimates with plasma phosphorylated tau concentrations.&#xD;
&#xD;
      This study will produce a benchmark dataset to develop methods for tau PET quantification and&#xD;
      harmonization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2027</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cross-sectional tau PET uptake values</measure>
    <time_frame>2 years from enrollment</time_frame>
    <description>Compare/harmonize cross-sectional tau deposition measurements (standardized uptake value ratio (SUVR)) obtained with Flortaupicir and MK-6240.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Longitudinal change in tau PET uptake values over 18 months</measure>
    <time_frame>5 years from enrollment</time_frame>
    <description>Compare/harmonize change in tau deposition measurements (standardized uptake value ratio (SUVR)) obtained with Flortaupicir and MK-6240 between baseline and 18-month follow-up assessments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Associations of tau PET uptake values with amyloid-β PET uptake values</measure>
    <time_frame>5 years from enrollment</time_frame>
    <description>Compare the effect size of the associations of tau deposition measurements (standardized uptake value ratio (SUVR)) obtained with Flortaupicir and MK-6240 with amyloid-β deposition measurements (SUVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associations of tau PET uptake values with measures of cognition</measure>
    <time_frame>5 years from enrollment</time_frame>
    <description>Compare the effect size of the associations of tau deposition measurements (standardized uptake value ratio (SUVR)) obtained with Flortaupicir and MK-6240 with cognitive measures assessed from neuropsychological evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associations of tau PET uptake values blood biomarkers</measure>
    <time_frame>5 years from enrollment</time_frame>
    <description>Compare the effect size of the associations of tau deposition measurements (standardized uptake value ratio (SUVR)) obtained with Flortaupicir and MK-6240 with blood-based biomarkers of tau.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">620</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Individuals across the aging and Alzheimer's disease (AD) spectrum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 620 individuals (40 young healthy, 280 cognitively unimpaired older, 200 mild cognitive impairment, and 100 Alzheimer's disease dementia) will be enrolled in the HEAD study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-Flortaucipir radiopharmaceutical</intervention_name>
    <description>Flortaucipir is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 10 millicuries of the radiopharmaceutical.</description>
    <arm_group_label>Individuals across the aging and Alzheimer's disease (AD) spectrum</arm_group_label>
    <other_name>18F-AV-1451, 18F-T807, Tauvid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-MK-6240 radiopharmaceutical</intervention_name>
    <description>MK-6240 is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 5 millicuries of the radiopharmaceutical.</description>
    <arm_group_label>Individuals across the aging and Alzheimer's disease (AD) spectrum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694)</intervention_name>
    <description>The clinical sites will use either PiB, Florbetaben, or NAV-4694 as the amyloid-β PET radiopharmaceutical. The amyloid-β PET radiopharmaceutical binds to amyloid-β plaques.&#xD;
Participants will receive a bolus intravenous injection of approximately 15 millicuries of the PiB radiopharmaceutical.&#xD;
Participants will receive a bolus intravenous injection of approximately 8 millicuries of the Florbetaben or NAV-4694 radiopharmaceutical.</description>
    <arm_group_label>Individuals across the aging and Alzheimer's disease (AD) spectrum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Have an informant who will be able to provide an independent evaluation of&#xD;
             functioning.&#xD;
&#xD;
          -  Willing and capable of undergoing repeated MR/PET imaging.&#xD;
&#xD;
          -  Fluent in a language approved by the coordinating center.&#xD;
&#xD;
          -  At screening, must have no cognitive impairment, or meet criteria for single- or&#xD;
             multiple-domain amnestic mild cognitive impairment or Alzheimer's disease dementia.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Inability to provide informed consent by self or by proxy.&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Have any condition or are taking any medication that could increase the risk to the&#xD;
             participant, limit the ability to tolerate or interfere with the results of the tests&#xD;
             and procedures (in the opinion of the investigator).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tharick Pascoal, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tharick Pascoal, MD PhD</last_name>
    <phone>412-246-5147</phone>
    <email>pascoalt@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Firoza Z Lussier, MSc</last_name>
    <phone>412-586-9012</phone>
    <email>lussierfz@upmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lawrence Berkeley National Laboratory</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suzanne Baker, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Soleimani-Meigooni, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Val Lowe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brian A Gordon, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tharick Pascoal, MD PhD</last_name>
      <email>pascoalt@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Firoza Z Lussier, MSc</last_name>
      <phone>412-586-9012</phone>
      <email>lussierfz@upmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hwamee Oh, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria B Pascual, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Research Centre for Studies in Aging</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4H1V3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Rosa-Neto, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>April 29, 2022</study_first_submitted>
  <study_first_submitted_qc>April 29, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2022</study_first_posted>
  <last_update_submitted>November 7, 2022</last_update_submitted>
  <last_update_submitted_qc>November 7, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Tharick Pascoal</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Tau PET</keyword>
  <keyword>Neurofibrillary tangles</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Tauopathies</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiopharmaceuticals</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data from this research will be shared with other researchers pursuant to the 02/26/2003 &quot;NIH Final Statement on Sharing Research Data&quot;. To protect participants' rights and confidentiality, identifiers will be removed from the data before they are shared. The board of PIs has primary oversight of the HEAD study resource sharing plan and will review all issues related to internal and external requests for HEAD data. Raw PET and MR data will be uploaded by clinical sites after acquisitions, whereas processed PET and MR data will be uploaded after completion of the baseline visit and after completion of the 18-month follow-up visit. Demographics, results from cognitive tests, Aβ status, tau Braak staging, and plasma assay results will also be available through the LONI platform.</ipd_description>
    <ipd_time_frame>Data from baseline and follow-up assessments will be available for sharing after the completion of the respective study visits.</ipd_time_frame>
    <ipd_access_criteria>Researchers will be able to download data upon request to the PIs. Data sharing requests will be overseen by the study and site PIs.</ipd_access_criteria>
    <ipd_url>http://www.loni.usc.edu/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

